a Advanced Eye Center , Post Graduate Institute of Medical Education and Research , Chandigarh , India.
b Department of Internal Medicine , Post Graduate Institute of Medical Education and Research , Chandigarh , India.
Ocul Immunol Inflamm. 2018;26(6):884-892. doi: 10.1080/09273948.2017.1400074. Epub 2017 Nov 30.
To study the safety and efficacy of intravitreal injection of dexamethasone implant in the management of posterior segment involvement in tubercular uveitis (TBU).
In this study, retrospective analysis of safety and efficacy of intravitreal injection of dexamethasone implant for various indications such as cystoid macular edema (CME), vitritis, or paradoxical worsening in TB-related intermediate uveitis, retinal vasculitis, and multifocal serpiginoid choroiditis (MSC) was performed.
The study included 17 patients (19 eyes; 7 males). IOP increased from 14.88 ± 2.68 mm Hg to 16.4 ± 5.82 mm Hg (p = 0.18) at 3 months. BCVA improved from 0.37 ± 0.35 to 0.27 ± 0.21 at 3 months (p = 0.03). CME resolved at 3 months and two patients with paradoxical worsening showed resolution within 1 month.
Intravitreal dexamethasone implant is safe and efficacious as an adjunct to ATT in reducing the central macular thickness, vitritis, and progression of choroiditis lesions in paradoxical worsening of MSC.
研究玻璃体内注射地塞米松植入物治疗结核性葡萄膜炎（TBU）后节受累的安全性和疗效。
本研究对玻璃体内注射地塞米松植入物治疗各种适应证（如黄斑囊样水肿[CME]、眼内炎或与 TB 相关的中间葡萄膜炎、视网膜血管炎和多灶性匐行性脉络膜炎[MSC]的反常恶化）的安全性和疗效进行回顾性分析。
该研究纳入了 17 名患者（19 只眼；7 名男性）。眼压在 3 个月时从 14.88±2.68mmHg 升高至 16.4±5.82mmHg（p=0.18）。BCVA 在 3 个月时从 0.37±0.35 提高至 0.27±0.21（p=0.03）。CME 在 3 个月时得到缓解，2 例反常恶化的患者在 1 个月内得到缓解。
玻璃体内注射地塞米松植入物作为 ATT 的辅助治疗，可安全有效地减轻中央黄斑厚度、眼内炎和 MSC 反常恶化中的脉络膜炎病变的进展。
Zotero 插件